MLTX – moonlake immunotherapeutics - class a ordinary shares (US:NASDAQ)
Stock Stats
News
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics (NASDAQ: MLTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions [Yahoo! Finance]
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 
Form DEFA14A MoonLake Immunotherapeut
Form ARS MoonLake Immunotherapeut For: Dec 31
Form DEF 14A MoonLake Immunotherapeut For: Jun 05
Form 8-K MoonLake Immunotherapeut For: Mar 10
Form SC 13D/A MoonLake Immunotherapeut Filed by: BIOTECHNOLOGY VALUE FUND L P
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.